IMCI Pharmaceuticals

growth-positive

IMCI Pharmaceuticals, an Israeli startup, is revolutionizing the medical cannabis industry by developing nanoparticles for more effective delivery of cannabinoids. The company partners with cannabis growers to extract cannabinoids and transform them into nanoparticles, offering three different products for chronic ailments. These products provide varying durations of relief and are designed to complement each other. IMCI is largely self-funded, with some support from the Israel Innovation Authority and an angel investor. The company plans to conduct human trials next year and aims to have its first product ready for market within a year. Despite challenges posed by the ongoing conflict in Gaza, IMCI is optimistic about its future and the potential of its innovative solutions.

growth-positive

IMCI Pharmaceuticals, a company specializing in medicinal cannabis, is developing pharma-grade products for therapeutic use. The companys iCann products deliver precise doses and are easy to use, making them suitable for any patient population. The products are designed to meet pharma standards and improve patient compliance and quality of life. IMCIs products use nanoparticle technology to improve therapeutic benefits and reduce dosage regimens and side effects. The company is currently in the final stages of product development and is shifting its focus to commercial manufacturing. IMCI is also open to strategic business collaborations with biopharmaceutical companies in Europe for global product distribution.

growth-positive

IMCI, an Israeli company founded by Alon Hershkovitz and Avi Yakobovich in 2018, is developing products to deliver precise and effective doses of medical cannabis in an easy-to-use administration. The company has developed three dosage forms: a fast-dissolving thin film, a long-acting muco-adhesive tablet, and a capsule. These products are designed to be more efficient and user-friendly than traditional methods of consumption, such as smoking or oil-based extracts. IMCI plans to begin operations in Germany within the next year, with Israel-based operations expected to start towards the end of next year. The company is also preparing to expand to Australia and the USA.

growth-positive

The article discusses five healthcare startups that are developing innovative pain management solutions. Finnish startup Mendolor has developed a pain measurement application that uses objective measures to gauge pain. Chilean startup VRx Medical has created a virtual reality software to distract children during injections. US-based biotech startup Regulonix is developing non-opioid therapeutics that relieve chronic pain. Israeli startup IMCI is developing cannabis-based medicines to treat neuropathic pain. Netherlands-based startup Reducept provides a digital pain training platform.